Rosetta Genomics Ltd (ROSG)

1.08
0.01 0.93
NASDAQ : Health Care
Prev Close 1.07
Open 1.08
Day Low/High 1.07 / 1.11
52 Wk Low/High 0.71 / 3.25
Volume 51.08K
Avg Volume 329.10K
Exchange NASDAQ
Shares Outstanding 20.85M
Market Cap 22.31M
EPS -1.10
P/E Ratio 1.01
Div & Yield N.A. (N.A)

Latest News

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement For Entire Suite Of Diagnostic Tests And Services

Rosetta Expands Managed Care Coverage With New Preferred Provider Agreement For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Stratose Inc.

Rosetta Genomics Receives Approval From New York State For HEME FISH-based Assays

Rosetta Genomics Receives Approval From New York State For HEME FISH-based Assays

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of...

Rosetta Genomics Announces Publication Of Data Confirming Analytical Validity Of Its Novel Thyroid Nodule Classification Assay

Rosetta Genomics Announces Publication Of Data Confirming Analytical Validity Of Its Novel Thyroid Nodule Classification Assay

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announced that data from the analytical validation of the Company's novel, microRNA-based assay for...

Rosetta Genomics Receives Approval From New York State For Four PCR-Based Assays

Rosetta Genomics Receives Approval From New York State For Four PCR-Based Assays

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces receipt of conditional approval from the New York State Department of Health...

Rosetta Genomics Reports 2016 First Quarter Financial Results

Rosetta Genomics Reports 2016 First Quarter Financial Results

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.

Rosetta Genomics To Host 2016 First Quarter Financial Results And Business Update Conference Call On May 19, 2016

Rosetta Genomics To Host 2016 First Quarter Financial Results And Business Update Conference Call On May 19, 2016

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three months ended March 31,...

Rosetta Genomics Reports 2015 Full Year Financial Results

Rosetta Genomics Reports 2015 Full Year Financial Results

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the 12 months ended December 31, 2015.

Rosetta Genomics To Host Business Update And 2015 Year-End Financial Results Conference Call On March 23, 2016

Rosetta Genomics To Host Business Update And 2015 Year-End Financial Results Conference Call On March 23, 2016

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.

Rosetta Genomics Appoints Ana C. Ward As Executive Vice President, Legal And Corporate Development

Rosetta Genomics Appoints Ana C. Ward As Executive Vice President, Legal And Corporate Development

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Ana C.

Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of Three New Product Offerings

Rosetta Genomics Expands Molecular Diagnostics Test Menu With Launch Of Three New Product Offerings

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces the launch of three high-value molecular diagnostic offerings in order to...

Rosetta Genomics Receives Approval From New York State For First-of-its-kind Thyroid Cancer Diagnostic Assay

Rosetta Genomics Receives Approval From New York State For First-of-its-kind Thyroid Cancer Diagnostic Assay

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces conditional approval status for RosettaGX Reveal™, its novel microRNA...

Rosetta Genomics To Present At Source Capital's 2016 Disruptive Growth & Healthcare Conference

Rosetta Genomics To Present At Source Capital's 2016 Disruptive Growth & Healthcare Conference

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company will be participating at Source Capital's 2016 Disruptive Growth &...

Rosetta Genomics Announces Agreement With America's Choice Provider Network For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Announces Agreement With America's Choice Provider Network For Entire Suite Of Diagnostic Tests And Services

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into an agreement with America's Choice Provider Network...

Rosetta Genomics Granted U.S. Patent Allowance For Use Of Gene Expression Signature For Classification Of Kidney Tumors

Rosetta Genomics Granted U.S. Patent Allowance For Use Of Gene Expression Signature For Classification Of Kidney Tumors

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent...

CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer

CORRECTING and REPLACING Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer

Headline of release should read: Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer (instead of Rosetta Genomics Granted U.

Rosetta Genomics Grants Sublicenses To Mirna Therapeutics For MicroRNA-related Patents For The Development Of Oncology Therapeutics

Rosetta Genomics Grants Sublicenses To Mirna Therapeutics For MicroRNA-related Patents For The Development Of Oncology Therapeutics

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the signing of an agreement with Mirna Therapeutics (NASDAQ: MIRN), for a worldwide...

Rosetta Genomics (ROSG) Stock Closed Up on Cantor Fitzgerald Rating

Rosetta Genomics (ROSG) Stock Closed Up on Cantor Fitzgerald Rating

Rosetta Genomics (ROSG) stock surged on Friday after Cantor Fitzgerald initiated coverage on the stock with a 'speculative buy' rating.

4 Biotech Stocks Under $10 Poised for Big Breakouts

4 Biotech Stocks Under $10 Poised for Big Breakouts

These biotech stocks are within range of triggering breakout trades. Here's how to trade them now.

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics And Biocept Advance Collaboration To Proof-of-Concept Studies Aimed At MicroRNA Profiling Of Circulating Tumor Cells To Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc.

Rosetta Genomics Reports Third Quarter 2015 Financial Results

Rosetta Genomics Reports Third Quarter 2015 Financial Results

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2015.

Rosetta Provides Update On Performance Data And Launch Of RosettaGX Reveal™ (Thyroid MicroRNA Classifier)

Rosetta Provides Update On Performance Data And Launch Of RosettaGX Reveal™ (Thyroid MicroRNA Classifier)

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces additional performance data from the recently-completed, blinded validation study of...

Rosetta Genomics Appoints Dr. Maria Fe Paz As Interim Chief Medical Officer

Rosetta Genomics Appoints Dr. Maria Fe Paz As Interim Chief Medical Officer

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Maria Fe Paz, M.

Rosetta Genomics Reports Financial Results For The First Half Of 2015

Rosetta Genomics Reports Financial Results For The First Half Of 2015

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the six months ended June 30, 2015.

Positive Performance Data From Validation Study Of Rosetta Genomics' MicroRNA-based Diagnostic Assay For Thyroid Nodule Classification Presented At The International Thyroid Congress And Annual Meeting Of The American Thyroid Association

Positive Performance Data From Validation Study Of Rosetta Genomics' MicroRNA-based Diagnostic Assay For Thyroid Nodule Classification Presented At The International Thyroid Congress And Annual Meeting Of The American Thyroid Association

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that performance and other data from the recently-completed, blinded validation study of its...

Rosetta Genomics To Host Business Update And Six Month Financials Conference Call On October 27, 2015

Rosetta Genomics To Host Business Update And Six Month Financials Conference Call On October 27, 2015

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.

Rosetta Genomics Raises $8,000,000 In Private Placement

Rosetta Genomics Raises $8,000,000 In Private Placement

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced it has entered into definitive agreements with investors to purchase an aggregate of...

Rosetta Genomics Launches BRAF Mutation Assay

Rosetta Genomics Launches BRAF Mutation Assay

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of a molecular test for BRAF mutation analysis to help personalize therapy for...

Rosetta Genomics To Present At 2015 Aegis Growth Conference

Rosetta Genomics To Present At 2015 Aegis Growth Conference

Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that Company management will participate in the upcoming 2015 Aegis Growth Conference being...